Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view.

Cancer Cancer outcomes Cancer progression Diabetes Glycemia Glycemic control

Journal

Journal of endocrinological investigation

ISSN: 1720-8386

Titre abrégé: J Endocrinol Invest

Pays: Italy

ID NLM: 7806594

Informations de publication

Date de publication:
27 Jun 2024

Historique:

received: 12 04 2024

accepted: 16 06 2024

medline: 27 6 2024

pubmed: 27 6 2024

entrez: 27 6 2024

Statut: aheadofprint

Résumé

Increasing evidence suggests that diabetes increases the risk of developing different types of cancer. Hyperinsulinemia, hyperglycemia and chronic inflammation, characteristic of diabetes, could represent possible mechanisms involved in cancer development in diabetic patients. At the same time, cancer increases the risk of developing new-onset diabetes, mainly caused by the use of specific anticancer therapies. Of note, diabetes has been associated with a ∼10% increase in mortality for all cancers in comparison with subjects who did not have diabetes. Diabetes is associated with a worse prognosis in patients with cancer, and more recent findings suggest a key role for poor glycemic control in this regard. Nevertheless, the association between glycemic control and cancer outcomes in oncologic patients with diabetes remains unsettled and poorly debated. The current review seeks to summarize the available evidence on the effect of glycemic control on cancer outcomes, as well as on the possibility that timely treatment of hyperglycemia and improved glycemic control in patients with cancer and diabetes may favorably affect cancer outcomes.

Sections du résumé

BACKGROUND BACKGROUND

PURPOSE OBJECTIVE

The current review seeks to summarize the available evidence on the effect of glycemic control on cancer outcomes, as well as on the possibility that timely treatment of hyperglycemia and improved glycemic control in patients with cancer and diabetes may favorably affect cancer outcomes.

Identifiants

DOI: 10.1007/s40618-024-02417-z PMID: 38935200

pubmed: 38935200

doi: 10.1007/s40618-024-02417-z

pii: 10.1007/s40618-024-02417-z

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

IDF Diabetes atlas. https://diabetesatlas.org/ . Accessed 11 Jan 2024

Biondi G, Marrano N, Borrelli A et al (2023) The p66Shc redox protein and the emerging complications of diabetes. Int J Mol Sci 25:108. https://doi.org/10.3390/IJMS25010108

doi: 10.3390/IJMS25010108 pubmed: 38203279 pmcid: 10778847

Gregg EW, Sattar N, Ali MK (2016) The changing face of diabetes complications. Lancet Diabetes Endocrinol 4:537–547. https://doi.org/10.1016/S2213-8587(16)30010-9

doi: 10.1016/S2213-8587(16)30010-9 pubmed: 27156051

Natalicchio A, Faggiano A, Zatelli MC et al (2022) Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): how do they influence each other? an Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 169:103572. https://doi.org/10.1016/J.CRITREVONC.2021.103572

doi: 10.1016/J.CRITREVONC.2021.103572 pubmed: 34954047

Cancer today. https://gco.iarc.fr/today/en/fact-sheets-populations#groups . Accessed 28 May 2024

Ling S, Brown K, Miksza JK et al (2020) Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people. Diabetes Care 43:2313–2322. https://doi.org/10.2337/DC20-0204

doi: 10.2337/DC20-0204 pubmed: 32910779

Pearson-Stuttard J, Papadimitriou N, Markozannes G et al (2021) Type 2 diabetes and cancer: an umbrella review of observational and mendelian randomization studies. Cancer Epidemiol Biomark Prev 30:1218–1228. https://doi.org/10.1158/1055-9965.EPI-20-1245

doi: 10.1158/1055-9965.EPI-20-1245

Hershey D (2017) Importance of glycemic control in cancer patients with diabetes: treatment through end of life. Asia Pac J Oncol Nurs 4:313. https://doi.org/10.4103/apjon.apjon_40_17

doi: 10.4103/apjon.apjon_40_17 pubmed: 28966959 pmcid: 5559941

Joharatnam-Hogan N, Chambers P, Dhatariya K, Board R (2022) A guideline for the outpatient management of glycaemic control in people with cancer. Diabet Med 39:e14636. https://doi.org/10.1111/DME.14636

doi: 10.1111/DME.14636 pubmed: 34240470

Lega IC, Lipscombe LL (2020) Review: diabetes, obesity, and cancer-pathophysiology and clinical implications. Endocr Rev 41:bnz014. https://doi.org/10.1210/ENDREV/BNZ014

doi: 10.1210/ENDREV/BNZ014 pubmed: 31722374

Hu Y, Zhang X, Ma Y et al (2021) Incident type 2 diabetes duration and cancer risk: a prospective study in two US cohorts. J Natl Cancer Inst 113:381–389. https://doi.org/10.1093/JNCI/DJAA141

doi: 10.1093/JNCI/DJAA141 pubmed: 33225344

Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674–1685. https://doi.org/10.2337/dc10-0666

doi: 10.2337/dc10-0666 pubmed: 20587728 pmcid: 2890380

Bansal D, Bhansali A, Kapil G et al (2013) Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis 16:151–158. https://doi.org/10.1038/PCAN.2012.40

doi: 10.1038/PCAN.2012.40 pubmed: 23032360

Cignarelli A, Genchi VA, Caruso I et al (2018) Diabetes and cancer: pathophysiological fundamentals of a ‘dangerous affair.’ Diabetes Res Clin Pract 143:378–388. https://doi.org/10.1016/j.diabres.2018.04.002

doi: 10.1016/j.diabres.2018.04.002 pubmed: 29679627

Key TJ, Appleby PN, Reeves GK et al (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11:530–542. https://doi.org/10.1016/S1470-2045(10)70095-4

doi: 10.1016/S1470-2045(10)70095-4 pubmed: 20472501

Heiden MGV, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029–1033. https://doi.org/10.1126/SCIENCE.1160809

doi: 10.1126/SCIENCE.1160809

Matsuda M, Shimomura I (2013) Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract 7:e330–e341. https://doi.org/10.1016/J.ORCP.2013.05.004

doi: 10.1016/J.ORCP.2013.05.004 pubmed: 24455761

Lee SC, Chan JCN (2015) Evidence for DNA damage as a biological link between diabetes and cancer. Chin Med J (Engl) 128:1543–1548. https://doi.org/10.4103/0366-6999.157693

doi: 10.4103/0366-6999.157693 pubmed: 26021514

Natalicchio A, Montagnani M, Gallo M et al (2023) MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)/Italian Association of Medical Diabetologists (AMD)/Italian Society of Diabetology (SID)/Italian Society of Endocrinology (SIE)/Italian Society of Pharmacology (SIF) multidisciplinary critical view. ESMO open 8:101573. https://doi.org/10.1016/J.ESMOOP.2023.101573

doi: 10.1016/J.ESMOOP.2023.101573 pubmed: 37263082 pmcid: 10245125

Renzelli V, Gallo M, Morviducci L et al (2023) Polybrominated diphenyl ethers (PBDEs) and human health: effects on metabolism, diabetes and cancer. Cancers (Basel) 15:4237. https://doi.org/10.3390/CANCERS15174237

doi: 10.3390/CANCERS15174237 pubmed: 37686512

Colhoun HM (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish diabetes research network epidemiology group. Diabetologia 52:1755–1765. https://doi.org/10.1007/S00125-009-1453-1

doi: 10.1007/S00125-009-1453-1 pubmed: 19603149 pmcid: 2723678

Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777. https://doi.org/10.1007/S00125-009-1440-6

doi: 10.1007/S00125-009-1440-6 pubmed: 19572116

Jonasson JM, Ljung R, Talbäck M et al (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52:1745–1754. https://doi.org/10.1007/S00125-009-1444-2

doi: 10.1007/S00125-009-1444-2 pubmed: 19588120

Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744. https://doi.org/10.1007/S00125-009-1418-4

doi: 10.1007/S00125-009-1418-4 pubmed: 19565214 pmcid: 2723679

Sciacca L, Vella V, Frittitta L et al (2018) Long-acting insulin analogs and cancer. Nutr Metab Cardiovasc Dis 28:436–443. https://doi.org/10.1016/J.NUMECD.2018.02.010

doi: 10.1016/J.NUMECD.2018.02.010 pubmed: 29609864

Wu JW, Filion KB, Azoulay L et al (2016) Effect of long-acting insulin analogs on the risk of cancer: a systematic review of observational studies. Diabetes Care 39:486–494. https://doi.org/10.2337/DC15-1816

doi: 10.2337/DC15-1816 pubmed: 26740633

Bordeleau L, Yakubovich N, Dagenais GR et al (2014) The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 37:1360–1366. https://doi.org/10.2337/DC13-1468

doi: 10.2337/DC13-1468 pubmed: 24574355

Gokhale M, Buse JB, Gray CL et al (2014) Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab 16:1247–1256. https://doi.org/10.1111/DOM.12379

doi: 10.1111/DOM.12379 pubmed: 25109825 pmcid: 4227935

R. Drab S, (2016) Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a clinical update of safety and efficacy. Curr Diabetes Rev 12:403–413. https://doi.org/10.2174/1573399812666151223093841

doi: 10.2174/1573399812666151223093841

Egan AG, Blind E, Dunder K et al (2014) Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med 370:794–797. https://doi.org/10.1056/NEJMP1314078

doi: 10.1056/NEJMP1314078 pubmed: 24571751

Abrahami D, Douros A, Yin H et al (2018) Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 363:k4880. https://doi.org/10.1136/BMJ.K4880

doi: 10.1136/BMJ.K4880 pubmed: 30518618 pmcid: 6278586

Marzioni M, Alpini G, Saccomanno S et al (2009) Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 58:990–997. https://doi.org/10.1136/GUT.2008.150870

doi: 10.1136/GUT.2008.150870 pubmed: 18829977

Marzioni M, Alpini G, Saccomanno S et al (2007) Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology 133:244–255. https://doi.org/10.1053/J.GASTRO.2007.04.007

doi: 10.1053/J.GASTRO.2007.04.007 pubmed: 17631146

FDA Drug Safety Communication: Update to ongoing safety review of actos (pioglitazone) and increased risk of bladder cancer FDA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-update-ongoing-safety-review-actos-pioglitazone-and-increased-risk . Accessed 23 Apr 2024

Lewis JD, Ferrara A, Peng T et al (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916–922. https://doi.org/10.2337/DC10-1068

doi: 10.2337/DC10-1068 pubmed: 21447663 pmcid: 3064051

Mehtälä J, Khanfir H, Bennett D et al (2018) Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. Diabetol Int 10:24–36. https://doi.org/10.1007/S13340-018-0360-4

doi: 10.1007/S13340-018-0360-4 pubmed: 30800561 pmcid: 6357234

Hsiao FY, Hsieh PH, Huang WF et al (2013) Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study. Drug Saf 36:643–649. https://doi.org/10.1007/S40264-013-0080-4

doi: 10.1007/S40264-013-0080-4 pubmed: 23797604

Reilly TP, Graziano MJ, Janovitz EB et al (2014) Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther 5:73–96. https://doi.org/10.1007/S13300-014-0053-3

doi: 10.1007/S13300-014-0053-3 pubmed: 24474422 pmcid: 4065287

De Jonghe S, Proctor J, Vinken P et al (2014) Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. Chem Biol Interact 224:1–12. https://doi.org/10.1016/J.CBI.2014.09.018

doi: 10.1016/J.CBI.2014.09.018 pubmed: 25289773

Tang H, Dai Q, Shi W et al (2017) SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia 60:1862–1872. https://doi.org/10.1007/S00125-017-4370-8

doi: 10.1007/S00125-017-4370-8 pubmed: 28725912

Hwangbo Y, Kang D, Kang M et al (2018) Incidence of diabetes after cancer development a Korean national cohort study. JAMA Oncol 4:1099–1105. https://doi.org/10.1001/jamaoncol.2018.1684

doi: 10.1001/jamaoncol.2018.1684 pubmed: 29879271 pmcid: 6143049

Currie CJ, Poole CD, Jenkins-Jones S et al (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299–304. https://doi.org/10.2337/dc11-1313

doi: 10.2337/dc11-1313 pubmed: 22266734 pmcid: 3263862

Seshasai SRK, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841. https://doi.org/10.1056/NEJMOA1008862

doi: 10.1056/NEJMOA1008862

Pearson-Stuttard J, Bennett J, Cheng YJ et al (2021) Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol 9:165–173. https://doi.org/10.1016/S2213-8587(20)30431-9

doi: 10.1016/S2213-8587(20)30431-9 pubmed: 33549162 pmcid: 7886654

Pearson-Stuttard J, Buckley J, Cicek M, Gregg EW (2021) The changing nature of mortality and morbidity in patients with diabetes. Endocrinol Metab Clin North Am 50:357–368. https://doi.org/10.1016/J.ECL.2021.05.001

doi: 10.1016/J.ECL.2021.05.001 pubmed: 34399950

Ranc K, Jørgensen ME, Friis S, Carstensen B (2014) Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia 57:927–934. https://doi.org/10.1007/S00125-014-3186-Z

doi: 10.1007/S00125-014-3186-Z pubmed: 24633676

de Haan-Du J, Groenier KH, Wauben-Spaetgens B et al (2023) The value of glycemic control prior to cancer diagnosis on all-cause mortality among patients with type 2 diabetes in Dutch primary care. Cancer Epidemiol Biomark Prev 32:252–259. https://doi.org/10.1158/1055-9965.EPI-22-0766

doi: 10.1158/1055-9965.EPI-22-0766

Li J, Ning N, ya, Rao Q xian, et al (2017) Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease. BMC Cancer 17:517. https://doi.org/10.1186/s12885-017-3510-3

doi: 10.1186/s12885-017-3510-3 pubmed: 28774279 pmcid: 5543538

Nik-Ahd F, Howard LE, Eisenberg AT et al (2019) Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: results from the SEARCH database. Cancer 125:2861–2867. https://doi.org/10.1002/cncr.32141

doi: 10.1002/cncr.32141 pubmed: 31034601

Chowdhury TA, Jacob P (2019) Challenges in the management of people with diabetes and cancer. Diabet Med 36:795–802. https://doi.org/10.1111/dme.13919

doi: 10.1111/dme.13919 pubmed: 30706527

Hershey DS, Tipton J, Given B, Davis E (2012) Perceived impact of cancer treatment on diabetes self-management. Diabetes Educ 38:779–790. https://doi.org/10.1177/0145721712458835

doi: 10.1177/0145721712458835 pubmed: 22983823

Gallo M, Muscogiuri G, Felicetti F et al (2018) Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. Metabolism 78:141–154. https://doi.org/10.1016/J.METABOL.2017.09.013

doi: 10.1016/J.METABOL.2017.09.013 pubmed: 28993227

Ashley L, Kassim S, Kellar I et al (2022) Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians. BMJ Open 12:e060402. https://doi.org/10.1136/BMJOPEN-2021-060402

doi: 10.1136/BMJOPEN-2021-060402 pubmed: 35193924 pmcid: 8867345

Hershey DS, Given B, Given C et al (2014) Predictors of diabetes self-management in older adults receiving chemotherapy. Cancer Nurs 37:97–105. https://doi.org/10.1097/NCC.0B013E3182888B14

doi: 10.1097/NCC.0B013E3182888B14 pubmed: 23519039

Zanders MMJ, Haak HR, van Herk-Sukel MPP et al (2015) Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia 58:951–960. https://doi.org/10.1007/S00125-015-3497-8

doi: 10.1007/S00125-015-3497-8 pubmed: 25638246

Pinheiro LC, Soroka O, Kern LM et al (2020) Diabetes care management patterns before and after a cancer diagnosis: a SEER-medicare matched cohort study. Cancer 126:1727–1735. https://doi.org/10.1002/CNCR.32728

doi: 10.1002/CNCR.32728 pubmed: 31999848

Shariff AI, Syed S, Shelby RA et al (2019) Novel cancer therapies and their association with diabetes. J Mol Endocrinol 62:R187–R199. https://doi.org/10.1530/JME-18-0002

doi: 10.1530/JME-18-0002 pubmed: 30532995

Silvestris N, Argentiero A, Beretta G et al (2020) Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 154:103066. https://doi.org/10.1016/J.CRITREVONC.2020.103066

doi: 10.1016/J.CRITREVONC.2020.103066 pubmed: 32853883

Ragni A, Retta F, Arvat E, Gallo M (2021) Diabetes in cancer patients: risks, goals and management. Front Horm Res 54:103–114. https://doi.org/10.1159/000513807

doi: 10.1159/000513807 pubmed: 33556942

Tsilidis KK, Kasimis JC, Lopez DS et al (2015) Type 2 diabetes and cancer: Umbrella review of meta-analyses of observationlal studies. BMJ 350:g7607. https://doi.org/10.1136/bmj.g7607

doi: 10.1136/bmj.g7607 pubmed: 25555821

Renehan AG, Yeh HC, Johnson JA et al (2012) Diabetes and cancer (2): evaluating the impact of diabetes on mortality In patients with cancer. Diabetologia 55:1619–1632. https://doi.org/10.1007/s00125-012-2526-0

doi: 10.1007/s00125-012-2526-0 pubmed: 22476948

Silvestris N, Argentiero A, Natalicchio A et al (2021) Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. ESMO open 6:100153. https://doi.org/10.1016/J.ESMOOP.2021.100153

doi: 10.1016/J.ESMOOP.2021.100153 pubmed: 33984679 pmcid: 8134762

Barua R, Templeton AJ, Seruga B et al (2018) Hyperglycaemia and survival in solid tumours: a systematic review and meta-analysis. Clin Oncol 30:215–224. https://doi.org/10.1016/j.clon.2018.01.003

doi: 10.1016/j.clon.2018.01.003

Hershey D, Hession S (2017) Chemotherapy and glycemic control in patients with type 2 diabetes and cancer: a comparative case analysis. Asia Pac J Oncol Nurs 4:224. https://doi.org/10.4103/apjon.apjon_22_17

doi: 10.4103/apjon.apjon_22_17 pubmed: 28695169 pmcid: 5473094

Sun HJ, Ohrr H, Sull JW et al (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194–202. https://doi.org/10.1001/JAMA.293.2.194

doi: 10.1001/JAMA.293.2.194

Boursi B, Giantonio BJ, Lewis JD et al (2016) Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome. Eur J Cancer 59:90–98. https://doi.org/10.1016/j.ejca.2016.02.018

doi: 10.1016/j.ejca.2016.02.018 pubmed: 27017290 pmcid: 4851868

Hammer MJ, Aouizerat BE, Schmidt BL et al (2015) Glycosylated hemoglobin A1c and lack of association with symptom severity in patients undergoing chemotherapy for solid tumors. Oncol Nurs Forum 42:581–590. https://doi.org/10.1188/15.ONF.581-590

doi: 10.1188/15.ONF.581-590 pubmed: 26488828

Ferrari P, Giardini A, Negri EM et al (2018) Managing people with diabetes during the cancer palliation in the era of simultaneous care. Diabetes Res Clin Pract 143:443–453. https://doi.org/10.1016/J.DIABRES.2017.12.010

doi: 10.1016/J.DIABRES.2017.12.010 pubmed: 29269136

Legris P, Bouillet B, Pâris J et al (2023) Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoring. Acta Diabetol 60:545–552. https://doi.org/10.1007/S00592-023-02032-Z

doi: 10.1007/S00592-023-02032-Z pubmed: 36637528

Lee AK, Warren B, Lee CJ et al (2018) The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care 41:104–111. https://doi.org/10.2337/DC17-1669

doi: 10.2337/DC17-1669 pubmed: 29127240

Huang WL, Huang KH, Huang CY et al (2020) Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study. BMC Urol 20:117. https://doi.org/10.1186/S12894-020-00684-5

doi: 10.1186/S12894-020-00684-5 pubmed: 32758196 pmcid: 7409398

ai YS, Chen CH, Huang CY, et al (2015) Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma. Diabetes Metab Res Rev 31:307–314. https://doi.org/10.1002/DMRR.2614

doi: 10.1002/DMRR.2614

Ahn JH, Il JS, Yim SU et al (2016) Impact of glycemic control and metformin use on the recurrence and progression of non-muscle invasive bladder cancer in patients with diabetes mellitus. J Korean Med Sci 31:1464–1471. https://doi.org/10.3346/JKMS.2016.31.9.1464

doi: 10.3346/JKMS.2016.31.9.1464 pubmed: 27510392 pmcid: 4974190

Hwang EC, Kim YJ, Hwang IS et al (2011) Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol 18:769–776. https://doi.org/10.1111/J.1442-2042.2011.02845.X

doi: 10.1111/J.1442-2042.2011.02845.X pubmed: 21914000

Eketunde AO (2020) Diabetes as a risk factor for breast cancer. Cureus 12:e8010. https://doi.org/10.7759/CUREUS.8010

doi: 10.7759/CUREUS.8010 pubmed: 32528752 pmcid: 7279688

Phillips AL, Reeves DJ, Storey S (2023) Impact of diabetes (type 2) and glycemic control on health-related outcomes of patients receiving chemotherapy for non-metastatic breast cancer: a retrospective analysis. Support Care Cancer 31:114. https://doi.org/10.1007/S00520-022-07563-9

doi: 10.1007/S00520-022-07563-9 pubmed: 36637522

Chang YL, Sheu WHH, Lin SY, Liou WS (2018) Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus. Clin Exp Med 18:383–390. https://doi.org/10.1007/s10238-018-0497-2

doi: 10.1007/s10238-018-0497-2 pubmed: 29572669

Erickson K, Patterson RE, Flatt SW et al (2011) Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol 29:54–60. https://doi.org/10.1200/JCO.2010.29.3183

doi: 10.1200/JCO.2010.29.3183 pubmed: 21115861

Cheung YMM, Hughes M, Harrod J et al (2022) The effects of diabetes and glycemic control on cancer outcomes in individuals with metastatic breast cancer. J Clin Endocrinol Metab 107:2511–2521. https://doi.org/10.1210/CLINEM/DGAC375

doi: 10.1210/CLINEM/DGAC375 pubmed: 35766387 pmcid: 9761575

Jousheghany F, Phelps J, Crook T, Hakkak R (2016) Relationship between level of HbA1C and breast cancer. BBA Clin 6:45–48. https://doi.org/10.1016/J.BBACLI.2016.04.005

doi: 10.1016/J.BBACLI.2016.04.005 pubmed: 27957429 pmcid: 5144103

Lee SJ, Kim JH, Park SJ et al (2017) Optimal glycemic target level for colon cancer patients with diabetes. Diabetes Res Clin Pract 124:66–71. https://doi.org/10.1016/j.diabres.2016.12.009

doi: 10.1016/j.diabres.2016.12.009 pubmed: 28107755

Ferroni P, Formica V, Della-Morte D et al (2016) Prognostic value of glycated hemoglobin in colorectal cancer. World J Gastroenterol 22:9984–9993. https://doi.org/10.3748/wjg.v22.i45.9984

doi: 10.3748/wjg.v22.i45.9984 pubmed: 28018105 pmcid: 5143765

Siddiqui AA, Spechler SJ, Huerta S et al (2008) Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci 53:2486–2494. https://doi.org/10.1007/s10620-008-0264-4

doi: 10.1007/s10620-008-0264-4 pubmed: 18409001

Meng Q, Yu Y, Wang K et al (2022) The prognostic role of fasting plasma glucose levels on survival in advanced colorectal cancer patients with type II diabetes mellitus: a retrospective cohort study. J Gastrointest Oncol 13:3080–3089. https://doi.org/10.21037/JGO-22-1124/COIF

doi: 10.21037/JGO-22-1124/COIF pubmed: 36636046 pmcid: 9830360

Kusne YN, Kosiorek HE, Buras MR et al (2020) Mortality and glycemic control among patients with diabetes mellitus and uterine or ovarian cancer. Futur Sci OA 7:FSO670. https://doi.org/10.2144/FSOA-2020-0158

doi: 10.2144/FSOA-2020-0158

Raffone A, Travaglino A, Saccone G et al (2019) Diabetes mellitus is associated with occult cancer in endometrial hyperplasia. Pathol Oncol Res 26:1377–1384. https://doi.org/10.1007/s12253-019-00684-3

doi: 10.1007/s12253-019-00684-3 pubmed: 31203571

Stevens EE, Yu S, Van Sise M et al (2012) Hemoglobin A1c and the relationship to stage and grade of endometrial cancer. Arch Gynecol Obstet 286:1507–1512. https://doi.org/10.1007/S00404-012-2455-7

doi: 10.1007/S00404-012-2455-7 pubmed: 22797661

Campbell PT, Newton CC, Freedman ND et al (2016) Body mass index, waist circumference, diabetes, and risk of liver cancer for U.S. adults. Cancer Res 76:6076–6083. https://doi.org/10.1158/0008-5472.CAN-16-0787

doi: 10.1158/0008-5472.CAN-16-0787 pubmed: 27742674 pmcid: 5141518

Cheuk-Fung Yip T, Wai-Sun Wong V, Lik-Yuen Chan H et al (2018) Effects of diabetes and glycemic control on risk of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol 16:765-773.e2. https://doi.org/10.1016/J.CGH.2017.12.009

doi: 10.1016/J.CGH.2017.12.009 pubmed: 29246694

Li CI, Chen HJ, Lai HC et al (2015) Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes–national cohort of Taiwan diabetes study. Int J cancer 136:2668–2679. https://doi.org/10.1002/IJC.29321

doi: 10.1002/IJC.29321 pubmed: 25387451

Kaneda K, Uenishi T, Takemura S et al (2012) The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 105:606–611. https://doi.org/10.1002/JSO.22137

doi: 10.1002/JSO.22137 pubmed: 22065536

Campbell PT, Newton CC, Jacobs EJ et al (2022) Prospective associations of hemoglobin A1c and c-peptide with risk of diabetes-related cancers in the cancer prevention study-II nutrition cohort. Cancer Res Commun 2:653–662. https://doi.org/10.1158/2767-9764.CRC-22-0082

doi: 10.1158/2767-9764.CRC-22-0082 pubmed: 36712480 pmcid: 9881454

Er KC, Hsu CY, Lee YK et al (2016) Effect of glycemic control on the risk of pancreatic cancer: a nationwide cohort study. Medicine (Baltimore) 95:e3921. https://doi.org/10.1097/MD.0000000000003921

doi: 10.1097/MD.0000000000003921 pubmed: 27311001

Dankner R, Boker LK, Boffetta P et al (2018) A historical cohort study on glycemic-control and cancer-risk among patients with diabetes. Cancer Epidemiol 57:104–109. https://doi.org/10.1016/J.CANEP.2018.10.010

doi: 10.1016/J.CANEP.2018.10.010 pubmed: 30388485

Alpertunga I, Sadiq R, Pandya D et al (2021) Glycemic control as an early prognostic marker in advanced pancreatic cancer. Front Oncol 11:571855. https://doi.org/10.3389/FONC.2021.571855

doi: 10.3389/FONC.2021.571855 pubmed: 33718132 pmcid: 7947820

Sandini M, Strobel O, Hank T et al (2020) Pre-operative dysglycemia is associated with decreased survival in patients with pancreatic neuroendocrine neoplasms. Surg (U.S.) 167:575–580. https://doi.org/10.1016/j.surg.2019.11.007

doi: 10.1016/j.surg.2019.11.007

Rajamanickam ESP, Christians KK, Aldakkak M et al (2017) Poor glycemic control is associated with failure to complete neoadjuvant therapy and surgery in patients with localized pancreatic cancer. J Gastrointest Surg 21:496–505. https://doi.org/10.1007/s11605-016-3319-4

doi: 10.1007/s11605-016-3319-4 pubmed: 27896658

Shi HJ, Jin C, Fu DL (2017) Impact of postoperative glycemic control and nutritional status on clinical outcomes after total pancreatectomy. World J Gastroenterol 23:265–274. https://doi.org/10.3748/wjg.v23.i2.265

doi: 10.3748/wjg.v23.i2.265 pubmed: 28127200 pmcid: 5236506

Rastmanesh R, Hejazi J, Marotta F, Hara N (2014) Type 2 diabetes: a protective factor for prostate cancer? an overview of proposed mechanisms. Clin Genitourin Cancer 12:143–148. https://doi.org/10.1016/J.CLGC.2014.01.001

doi: 10.1016/J.CLGC.2014.01.001 pubmed: 24513117

Lin CC, Wu MF, Chang YL et al (2022) Glycemic control was associated with nonprostate cancer and overall mortalities in diabetic patients with prostate cancer. J Chin Med Assoc 85:331–340. https://doi.org/10.1097/JCMA.0000000000000623

doi: 10.1097/JCMA.0000000000000623 pubmed: 34561410

Lee H, Kuk H, Byun SS et al (2015) Preoperative glycemic control status as a significant predictor of biochemical recurrence in prostate cancer patients after radical prostatectomy. PLoS ONE 10:e0124761. https://doi.org/10.1371/journal.pone.0124761

doi: 10.1371/journal.pone.0124761 pubmed: 25897669 pmcid: 4405577

Park J, Cho SY, Lee YJ et al (2014) Poor glycemic control of diabetes mellitus is associated with higher risk of prostate cancer detection in a biopsy population. PLoS ONE 9:e104789. https://doi.org/10.1371/JOURNAL.PONE.0104789

doi: 10.1371/JOURNAL.PONE.0104789 pubmed: 25198675 pmcid: 4157745

Kim HS, Presti JC, Aronson WJ et al (2010) Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate 70:1540–1546. https://doi.org/10.1002/pros.21189

doi: 10.1002/pros.21189 pubmed: 20687228 pmcid: 2930134

Brunello A, Kapoor R, Extermann M (2011) Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol 34:292–296. https://doi.org/10.1097/COC.0b013e3181e1d0c0

doi: 10.1097/COC.0b013e3181e1d0c0 pubmed: 20622641

Sung KH, Seung TL, Sung SK et al (2009) Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer. Prostate 69:820–826. https://doi.org/10.1002/PROS.20932

doi: 10.1002/PROS.20932

Joentausta RM, Kujala PM, Visakorpi T et al (2016) Tumor features and survival after radical prostatectomy among antidiabetic drug users. Prostate Cancer Prostatic Dis 19:367–373. https://doi.org/10.1038/pcan.2016.32

doi: 10.1038/pcan.2016.32 pubmed: 27502739

Silvestris N, Franchina T, Gallo M et al (2023) Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper. ESMO Open 8:102062. https://doi.org/10.1016/J.ESMOOP.2023.102062

doi: 10.1016/J.ESMOOP.2023.102062 pubmed: 38070434 pmcid: 10714217

Najafi F, Rajati F, Sarokhani D et al (2023) The relationship between metformin consumption and cancer risk: an updated umbrella review of systematic reviews and meta-analyses. Int J Prev Med 14:90. https://doi.org/10.4103/IJPVM.IJPVM_62_21

doi: 10.4103/IJPVM.IJPVM_62_21 pubmed: 37854987 pmcid: 10580191

Copur S, Yildiz AB, Covic A, Kanbay M (2023) Is there any robust evidence showing that SGLT2 inhibitor predisposes to cancer? Eur J Clin Invest 54:e14131. https://doi.org/10.1111/ECI.14131

doi: 10.1111/ECI.14131 pubmed: 38010034

Dicembrini I, Nreu B, Mannucci E, Monami M (2019) Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 21:1871–1877. https://doi.org/10.1111/DOM.13745

doi: 10.1111/DOM.13745 pubmed: 30972917